Browse diseases

…provement on optical coherence tomography in most patients with diabetic macular oedema. The treatment interval of ≤Q8 reflects adequate drug durabilit…

…city of biosimilar aflibercept (MYL-1701P) in participants with diabetic macular oedema who completed the 52-week global phase III trial and were enrol…

…nt) at fixed 4-month intervals in treatment-naïve patients with diabetic macular oedema (DMO) and retinal vein occlusion (RVO), stratified by baseline …

… and 2-year outcomes of eyes with persistent and non-persistent diabetic macular oedema (DME) treated with vascular endothelial growth factor (VEGF) in…

…ases, such as macular degeneration, diabetic macular oedema and venous occlusion, have increased significantly in recent decades, driving demand…

…as age-related macular degeneration (AMD) (68.97%), followed by diabetic macular oedema (DME) (30.17%) and retinal vein occlusion (RVO) (0.86%). Most p…

…l dexamethasone implants are used in hospital settings to treat diabetic macular oedema (DME) and macular oedema secondary to retinal vein occlusion (R…

…macular degeneration (nAMD), diabetic macular oedema (DME), and retinal vein occlusion (RVO). In the last 5 years, new molecules, extended dosing inte…

…ment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both…

…the treatment of wet age-related macular degeneration (AMD) and diabetic macular oedema (DME) in adults.Aim and Objectives To evaluate the use of aflib…

…sults A total of 529 AMD and 261 DME patients were analysed. In AMD, 276 patients were treated with aflibercept and 253 with ranibi…

…betic macular oedema (DMO), choroidal neovascularisation (CNV), retinal vein occlusion (RVO) and other eye diseases.Suspected cases of endophthalmitis…